leisure time -WSS

leisure time

author：explore 2025-09-27 16:47:10 - browse：79353

This is the inaugural edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

Hello! Welcome to the premiere issue of Adam’s Biotech Scorecard. I’m excited to get started. Let’s do this! (By the way, the AF in the logo are my initials, not the “other” AF.)

The contrarian view of Viking Therapeutics

Closeup financial chart

The developer of a dual-acting GLP-1/GIP treatment for obesity is riding high on positive data and takeout speculation. The drug, called VK2735, has shown impressive weight loss with minimal gastrointestinal side effects in both subcutaneous and oral formulations, positioning it as a strong challenger to the obesity juggernauts from Eli Lilly and Novo Nordisk. With a stock price that has soared nearly 800% over the past year, Viking is now a $9 billion company and a prime acquisition target for a cash-rich pharma company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

entertainment

knowledge

WSS

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Organ aging and disease risk measured by new blood test

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Pushing for an NIH office for post

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

How to pay for weight loss drugs and save Medicare

leisure time

leisure time

The contrarian view of Viking Therapeutics

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

Fetal surgery at risk from Dobbs and new abortion restrictions

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

ReNAgade cuts staff seven months after raising $300 million

After affirmative action ruling, medical educators look to 'holistic review'

ReNAgade cuts staff seven months after raising $300 million

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why scientists need input from humanists on sensitive research

The cancer drug shortage isn’t new — and neither are the solutions

UnitedHealth’s Optum accused of antitrust violations in California

Wikipedia

Takeda, Janssen join wearable maker to measure scratching

How to save health care price transparency rules

FDA advisers back CAR

The EPA's new lead rule: How one expert crunched the numbers

UnitedHealth’s Optum accused of antitrust violations in California

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

entertainment

knowledge

knowledge

entertainment